bioRxiv Science⌕ Search

Biology subjects

Suravajhala, R.

Publications and source records attributed to Suravajhala, R..

2 recordsLinked to original sources

Azole resistance: Insights from Y132 substitutions in Candida sterol 14α-demethylase

BackgroundAzole-resistant Candida infections are on the rise. Resistant substitutions at Y132 in sterol 14-demethylase, the key target of azole drugs, are frequent. However, it is unclear why only some Y132 substitutions are favoured or how they exert differential effects on different azoles. Materials and MethodsReported instances of Y132 substitutions were collected from the literature. Extensive molecular dynamics simulations of sterol 14-demethylase bound to fluconazole or VT1161 (VT1) were performed, and the ligand-binding free energies were computed to quantify the effects of various Y132 substitutions on azole binding/interactions. ResultsThree azole-resistant substitutions, Y to C/F/H, were reported at residue position 132 in sterol 14-demethylase. The Y132H was the most common substitution in C. albicans, while it was Y132F in other species. Ligand-binding free energies were -13.81 kcal/mol and -35.04 kcal/mol for fluconazole and VT1, respectively. There were differences in the ligand-binding free energies after substitutions compared to the wild type protein. ConclusionY132F and Y132H were the most frequent substitutions in Candida sterol 14-demethylase. Far higher binding free energy of fluconazole in comparison with VT1 might partly explain its susceptibility to azole-resistant substitutions. The results give key insights into azole resistance, and antifungal drug discovery and optimization.

bioinformatics↗

In silico approaches to identify the role of lncRNAs in Prostate cancer and Androgen receptor-targeted proteins

Long non-coding RNA (lncRNAs) are known to have a role in pathogenesis of a broad spectrum of malignancies.These are found to have a significant role as signal transduction mediators in cancer signaling pathways. Prostate Cancer (PCa) is emerging with increasing cases worldwide even as advanced approaches in clinical diagnosis and treatment of PCa are still challenging to address. To enhance patient stratification, there is an indefatigable need to understand risk that can allow new approaches of treatment based on prognosis. While PCa is known to have mediated androgen receptor (AR) stimulation, the latter plays a key role in regulating transcription of genes via nuclear translocation which in turn leads to response to androgens. LncRNAs have been implicated in developing clinical diagnostic and prognostic biomarkers in a broad spectrum of cancers. In our present study, 12 lncRNAs identified from clinical samples from our erstwhile PCa patients were docked with PCa and AR targeted 36 proteins. We identified three lncRNAs, viz. SCARNA10, NPBWR1, ANKRD20A9P are common between the targeted proteins and discern that SCARNA10 lncRNA could serve as a prognostic signature for PCa and AR biogenesis. We also sought to check the coding potential of interfacial residues associated with lncRNA docking sites.x

bioinformatics↗